Clinical trials: Electrocardiograph
- Condition Electrocardiograph
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT01511029
- Testing
- Dexpramipexole, Moxifloxacin
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Healthy, Atrial Fibrillation
Validation of the Performance of the Electrocardiogram (ECG) Function in the Masimo INVSENSOR00057
The objective of this study is to validate the performance of the electrocardiogram (ECG) function of the Masimo INVSENSOR00057 against contemporaneous measurements
- Trial name
- NCT06071754
- Testing
- Masimo INVSENSOR00057
- Where
- 4 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Healthy Volunteer
A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects
The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.
- Trial name
- NCT01461460
- Testing
- TR-701 FA 1200 mg, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pharmacokinetics
Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study
This study will characterize the pharmacokinetics of colchicine after an oral dosing regimen of 4.8 mg over 6 hours. In addition it will compare the electrocardiogram (ECG) changes, if any, from this dosing regimen to that of a…
- Trial name
- NCT01018420
- Testing
- Colchicine, Moxifloxacin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Cardiomyopathies, Cardiac Arrest
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
WILLEM is a multi-center, prospective and retrospective cohort study. The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal…
- Conditions
- Cardiomyopathies, Cardiac Arrest, Cardiac Arrhythmias, Sudden Cardiac Death
- Trial name
- WILLEM (NCT05890716)
- Testing
- AI-powered ECG analysis to detect cardiac arrhythmic episodes
- Where
- 13 sites in Netherlands, Spain
- Volunteers
- 5,342 people, healthy volunteers welcome
- Sponsor
- Idoven 1903 S.L.
Vital Signs
Comparison of Resting Heart and Respiratory Rate Measurements Acquired by Contactless Radar Sensors, Electrocardiography, and Capnography
1. Determine agreement (accuracy) of resting heart rate measured by Vitalpercept when compared to an FDA-cleared electrocardiograph (ECG) device, LifeSignals Wireless Biosensor. 2.
- Trial name
- Vitalpercept (NCT04935190)
- Testing
- Vitalpercept
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- DawnLight
Cystic Fibrosis
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
- Trial name
- NCT05867147
- Testing
- Vanzacaftor, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy Subjects
Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects
Primary: To assess the effects of ascending repeated-doses of oral [p.o.] neramexane at therapeutic and supra-therapeutic steady-state doses on cardiac repolarisation (QT/QTc interval) in healthy male and female subjects.
- Trial name
- NCT00978614
- Testing
- Neramexane
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Pregnancy
Fetal Electrocardiogram Extraction-Pilot Study
This is a pilot study utilizing trans-abdominal ECG and Doppler Ultrasounds to assess the feasibility of extracting fECGs in a volunteer population.
- Trial name
- NCT01681498
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Huntleigh Healthcare Ltd
Cardiac Repolarization in Healthy Subjects
4-way Crossover QT Evaluation in Healthy Subjects
The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical…
- Trial name
- NCT03709927
- Testing
- ZTI-01, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Nabriva Therapeutics AG
COPD, Hypertension
Sleepiz One+ Versus Capnography and Electrocardiography
EtCO2, or exhaled carbon dioxide, is a non-invasive and commonly used measure for respiratory rate and function. It can be easily monitored using a device called a capnograph, which consists of a sensor that is placed near the…
- Conditions
- COPD, Hypertension, Sleep Apnea, Asthma
- Trial name
- SPZCAP (NCT05712226)
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Arrhythmia
Clinical Performance Evaluation of the Hativ P30
Hativ P30 is intended to record, store, and transfer one-and two-channel ECG rhythms, and analyze them based on an artificial intelligence (AI) algorithm. In single channel mode, Hativ P30 can record lead-I.
- Trial name
- NCT06713226
- Testing
- Hativ P30 and 12-lead ECG comparator device
- Volunteers
- healthy volunteers welcome
- Sponsor
- VUNO Inc.
Pulmnary Hypertension
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
This prospective, observational study will evaluate whether synchronized heart sound (phonocardiogram, PCG) and three-lead electrocardiogram (ECG) recordings (entered as separate interventions in PRS, though collected together in…
- Trial name
- EKO-PH (NCT07136623)
- Testing
- Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording
- Where
- 2 sites in United States
- Volunteers
- 1,513 people, healthy volunteers welcome
- Sponsor
- Eko Devices, Inc.
Infections, Respiratory Tract
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
This is Phase I, 4-period, randomized, active-and placebo-controlled, double-blind crossover, single-dose study to evaluate the effects of a therapeutic (1000 milligram [mg]) and supratherapeutic (1800 mg) dose of GSK2140944 with…
- Trial name
- NCT02257398
- Testing
- GSK2140944, Moxifloxacin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects
A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects
- Trial name
- NCT04250506
- Testing
- Daridorexant, Moxifloxacin
- Where
- Czechia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Coronary Artery Disease
A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease
Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85.
- Trial name
- NCT00413647
- Testing
- CardioPET
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Healthy Subjects
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
This Phase 1, randomized, three period, placebo- and positive-controlled,double-blind, double-dummy, crossover study will be performed with approximately 80 healthy male and female subjects.
- Trial name
- NCT00672399
- Testing
- exenatide, Moxifloxacin
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pediculosis
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers.
- Trial name
- NCT01518699
- Testing
- Ha44, Moxifloxacin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Safety, Peripheral Neuropathy
Xanamem™ in Healthy Elderly Subjects
Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body.
- Conditions
- Safety, Peripheral Neuropathy, Cortisol, Central Nervous System
- Trial name
- XanaHES (NCT03830762)
- Testing
- Xanamem
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical